The firms said that the deal will provide access to Tempus' testing menu for healthcare providers at 800 cancer care locations that use Flatiron's OncoEMR platform.

EXTON, PA / ACCESSWIRE / November 12, 2024 / Frontage Laboratories, Inc ., a global CRO, and Medicover Integrated Clinical ...

Myriad Genetics and agency partner S50 Health educated OBGYNs and their patients in a campaign called “Getting Ahead of ...

Chicago-based Tempus said that the deal will provide access to its testing menu for about 4,200 healthcare providers at 800 cancer ... xG/xG+ hereditary cancer germline tests powered by Ambry Genetics ...

Biongevity introduces its one-of-a-kind initiatives to promote longevity and healthspan of users across the UAE Dubai, UAE: ...

Analyst Puneet Souda of Leerink Partners maintained a Buy rating on Myriad Genetics (MYGN – Research Report), reducing the price target ...

Biongevity introduces its one-of-a-kind initiatives to promote longevity and healthspan of users across the UAE ...

Lefkofsky’s comment reflects concerns about the testing industry. One of Ambry’s main competitors ... In 2014, Dunlop won a ...

Q3 2024 Earnings Call Transcript November 7, 2024 Pacific Biosciences of California, Inc. beats earnings expectations.

Myriad Genetics ( (MYGN) ) has released its Q3 earnings. Here is a breakdown of the information Myriad Genetics presented to its investors.

Myriad Genetics delivers strong third-quarter results, driven by growth within Pharmacogenomics and Prenatal. The company ...